NCT00394199已完成3 期
A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent & Adult Patients With Mild to Moderate Asthma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 357
- 试验地点
- 2
- 主要终点
- Change in Forced Expiratory volume in 1 s (FEV-1) from morning predose at Baseline (Week 0) to predose at Week 12
研究概览
简要总结
To compare the efficacy and safety of the fixed combination asthma drug Flutiform HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, in adult and adolescent patients with mild to moderate asthma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •History of asthma for at least 12 months
- •For steriod-requiring patients, documented use of inhaled corticosteroid for at least 4 weeks prior to Screening Visit
- •For steroid-free patients, no history of inhaled steroid asthma medication for at least 12 weeks prior to Screening Visit
- •Demonstrate FEV-1 of 60-85% of predicted normal values at Screening and Baseline Visit
- •Documented reversibility of 15% within 12 months of Screening or at Screening Visit (15% increase from pre-FEV-1 levels following albuterol inhalation or nebulized albuterol administration)
- •Symptoms of asthma during Run-in
- •Females of childbearing potential must have a negative urine pregnancy test at Screening and Baseline Visits. Females are eligible only if they are not pregnant or lactating, and are either sterile, or using acceptable methods of contraception.
- •Must otherwise be healthy
- •Provide written informed consent. Wishes of minors must be respected.
排除标准
- •Patients will not be eligible for the study if they meet any of the following criteria:
- •Life-threatening asthma within the past year or during the Run-In Period.
- •History of systemic corticosteroid medication within 3 months before the Screening Visit.
- •History of omalizumab use within past 6 months.
- •History of leukotriene receptor antagonist use, e.g., montelukast, within past week.
- •Current evidence or history of any clinically significant disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia.
- •Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during Run-In Period.
- •Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease [COPD], cystic fibrosis, bronchiectasis).
- •Known Human Immunodeficiency Virus (HIV)-positive status.
- •Smoking history equivalent to "10 pack years".
- •Current smoking history within 12 months prior to Screening Visit.
- •Current evidence or history of alcohol and/or substance abuse within 12 months prior to Screening Visit.
- •Patients who are confined in institution.
研究组 & 干预措施
3
Active Comparator
Formoterol 10
干预措施: Formoterol fumarate 10 (Drug)
1
Experimental
FlutiForm 100/10ug
干预措施: Fluticasone propionate/Formoterol Fumarate 100/10 (Drug)
2
Experimental
Fluticasone 100
干预措施: Fluticasone propionate 100 (Drug)
结局指标
主要结局
Change in Forced Expiratory volume in 1 s (FEV-1) from morning predose at Baseline (Week 0) to predose at Week 12
时间窗: Week 0 and 12
次要结局
- Other pulmonary function tests including forced vital capacity (FVC) and peak expiratory flow rate (PEFR).(Whole duration of study)
- Clinical endpoints (frequency of asthma exacerbations and patient data captured in diary including daily morning and evening PEFR).(Whole duration of study)
- Safety variables include adverse events, ECGs, clinical laboratory tests and vital signs.(Whole duration of study)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe AsthmaAsthmaNCT00393952SkyePharma AG557
已完成
3 期
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With AsthmaAsthmaNCT00393991SkyePharma AG475
已完成
3 期
Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric PatientsAsthmaNCT01511367Mundipharma Research Limited498
已完成
2 期
Flutiform® Compared With Seretide® in the Treatment of COPDChronic Obstructive Pulmonary DiseaseNCT02195375Mundipharma Research Limited923
已完成
3 期
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaAsthmaNCT06502366AstraZeneca424